vs
ENNIS, INC.（EBF）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
ENNIS, INC.的季度营收约是RIGEL PHARMACEUTICALS INC的1.4倍（$100.2M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 10.8%，领先373.2%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 0.4%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 1.4%）
ENNIS, INC.是北美领先的商业印刷产品及相关服务供应商，提供定制商业单据、压敏标签、营销宣传物料、促销品、品牌包装等产品，服务覆盖零售、医疗、金融服务及中小企业等多个领域的客户。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
EBF vs RIGL — 直观对比
营收规模更大
EBF
是对方的1.4倍
$69.8M
营收增速更快
RIGL
高出20.8%
0.4%
净利率更高
RIGL
高出373.2%
10.8%
两年增速更快
RIGL
近两年复合增速
1.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $100.2M | $69.8M |
| 净利润 | $10.8M | $268.1M |
| 毛利率 | 31.9% | 91.5% |
| 营业利润率 | 15.0% | 33.2% |
| 净利率 | 10.8% | 384.0% |
| 营收同比 | 0.4% | 21.2% |
| 净利润同比 | 6.1% | 1769.2% |
| 每股收益（稀释后） | $0.42 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBFRIGL
| Q4 25 | $100.2M | $69.8M | ||
| Q3 25 | $98.7M | $69.5M | ||
| Q2 25 | $97.2M | $101.7M | ||
| Q1 25 | $92.7M | $53.3M | ||
| Q4 24 | $99.8M | $57.6M | ||
| Q3 24 | $99.0M | $55.3M | ||
| Q2 24 | $103.1M | $36.8M | ||
| Q1 24 | $97.4M | $29.5M |
净利润EBFRIGL
| Q4 25 | $10.8M | $268.1M | ||
| Q3 25 | $13.2M | $27.9M | ||
| Q2 25 | $9.8M | $59.6M | ||
| Q1 25 | $9.0M | $11.4M | ||
| Q4 24 | $10.2M | $14.3M | ||
| Q3 24 | $10.3M | $12.4M | ||
| Q2 24 | $10.7M | $-1.0M | ||
| Q1 24 | $10.1M | $-8.2M |
毛利率EBFRIGL
| Q4 25 | 31.9% | 91.5% | ||
| Q3 25 | 30.5% | 93.2% | ||
| Q2 25 | 31.1% | 95.6% | ||
| Q1 25 | 29.5% | 91.7% | ||
| Q4 24 | 29.3% | 89.9% | ||
| Q3 24 | 30.1% | 85.5% | ||
| Q2 24 | 30.0% | 92.4% | ||
| Q1 24 | 28.4% | 93.1% |
营业利润率EBFRIGL
| Q4 25 | 15.0% | 33.2% | ||
| Q3 25 | 12.5% | 40.9% | ||
| Q2 25 | 13.7% | 60.1% | ||
| Q1 25 | 13.0% | 23.9% | ||
| Q4 24 | 13.1% | 28.9% | ||
| Q3 24 | 13.3% | 25.4% | ||
| Q2 24 | 13.3% | 1.2% | ||
| Q1 24 | 13.3% | -23.6% |
净利率EBFRIGL
| Q4 25 | 10.8% | 384.0% | ||
| Q3 25 | 13.3% | 40.2% | ||
| Q2 25 | 10.1% | 58.6% | ||
| Q1 25 | 9.7% | 21.5% | ||
| Q4 24 | 10.2% | 24.9% | ||
| Q3 24 | 10.4% | 22.5% | ||
| Q2 24 | 10.4% | -2.8% | ||
| Q1 24 | 10.4% | -27.9% |
每股收益（稀释后）EBFRIGL
| Q4 25 | $0.42 | $14.11 | ||
| Q3 25 | $0.51 | $1.46 | ||
| Q2 25 | $0.38 | $3.28 | ||
| Q1 25 | $0.34 | $0.63 | ||
| Q4 24 | $0.39 | $0.82 | ||
| Q3 24 | $0.40 | $0.70 | ||
| Q2 24 | $0.41 | $-0.06 | ||
| Q1 24 | $0.39 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $304.8M | $391.5M |
| 总资产 | $354.3M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EBFRIGL
| Q4 25 | $31.3M | $155.0M | ||
| Q3 25 | $31.9M | $137.1M | ||
| Q2 25 | $32.6M | $108.4M | ||
| Q1 25 | $72.5M | $77.1M | ||
| Q4 24 | $68.6M | $77.3M | ||
| Q3 24 | $122.6M | $61.1M | ||
| Q2 24 | $123.7M | $49.1M | ||
| Q1 24 | $110.9M | $49.5M |
总债务EBFRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益EBFRIGL
| Q4 25 | $304.8M | $391.5M | ||
| Q3 25 | $305.4M | $117.6M | ||
| Q2 25 | $301.2M | $81.9M | ||
| Q1 25 | $302.0M | $18.6M | ||
| Q4 24 | $297.7M | $3.3M | ||
| Q3 24 | $358.4M | $-14.6M | ||
| Q2 24 | $354.4M | $-29.9M | ||
| Q1 24 | $349.8M | $-31.7M |
总资产EBFRIGL
| Q4 25 | $354.3M | $513.6M | ||
| Q3 25 | $361.8M | $242.5M | ||
| Q2 25 | $361.7M | $206.7M | ||
| Q1 25 | $348.9M | $176.0M | ||
| Q4 24 | $346.1M | $164.0M | ||
| Q3 24 | $406.8M | $139.4M | ||
| Q2 24 | $406.2M | $128.4M | ||
| Q1 24 | $399.2M | $126.5M |
负债/权益比EBFRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $15.7M | — |
| 自由现金流率自由现金流/营收 | 15.7% | — |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | 1.52× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $42.5M | — |
8季度趋势，按日历期对齐
经营现金流EBFRIGL
| Q4 25 | $16.4M | $22.0M | ||
| Q3 25 | $10.5M | $24.0M | ||
| Q2 25 | $8.0M | $30.5M | ||
| Q1 25 | $12.8M | $-893.0K | ||
| Q4 24 | $18.2M | $14.5M | ||
| Q3 24 | $11.8M | $21.7M | ||
| Q2 24 | $23.1M | $302.0K | ||
| Q1 24 | $16.6M | $-5.0M |
自由现金流EBFRIGL
| Q4 25 | $15.7M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $11.1M | — | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $20.6M | — | ||
| Q1 24 | $15.0M | — |
自由现金流率EBFRIGL
| Q4 25 | 15.7% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 17.6% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 20.0% | — | ||
| Q1 24 | 15.3% | — |
资本支出强度EBFRIGL
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.7% | — |
现金转化率EBFRIGL
| Q4 25 | 1.52× | 0.08× | ||
| Q3 25 | 0.80× | 0.86× | ||
| Q2 25 | 0.81× | 0.51× | ||
| Q1 25 | 1.41× | -0.08× | ||
| Q4 24 | 1.78× | 1.01× | ||
| Q3 24 | 1.15× | 1.75× | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
